Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Current Deferred Revenue (2018 - 2021)

Entera Bio has reported Current Deferred Revenue over the past 4 years, most recently at $15000.0 for Q4 2021.

  • For the quarter ending Q4 2021, Current Deferred Revenue fell 90.51% year-over-year to $15000.0, compared with a TTM value of $15000.0 through Dec 2021, down 90.51%, and an annual FY2021 reading of $15000.0, down 90.51% over the prior year.
  • Current Deferred Revenue came in at $15000.0 for Q4 2021, up from $8000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $267000.0 in Q4 2019 to a low of $8000.0 in Q2 2021.
  • Median Current Deferred Revenue over the past 4 years was $154500.0 (2019), compared with a mean of $139666.7.
  • The sharpest move saw Current Deferred Revenue skyrocketed 35.16% in 2020, then crashed 95.38% in 2021.
  • Over 4 years, Current Deferred Revenue stood at $225000.0 in 2018, then grew by 18.67% to $267000.0 in 2019, then tumbled by 40.82% to $158000.0 in 2020, then plummeted by 90.51% to $15000.0 in 2021.
  • Per Business Quant, the three most recent readings for ENTX's Current Deferred Revenue are $15000.0 (Q4 2021), $8000.0 (Q2 2021), and $15000.0 (Q1 2021).